Response to Comments: MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis

This document (A59534) is an administrative response-to-comments notice regarding MolDX LCD L39481 and does not itself provide clinical coverage criteria. It records the comment period (2022-09-29 to 2022-11-12), notice start (2023-08-31), and LCD effective date (2023-10-15). For specific coverage, medical necessity, and testing criteria, review MolDX LCD L39481.

"This document does not contain clinical coverage criteria for molecular biomarker testing to guide targeted therapy in rheumatoid arthritis; refer to MolDX Local Coverage Determination L39481 for c..."

Sign up to see full coverage criteria, indications, and limitations.